Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. lifted its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 1,496.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 17,974 shares of the company’s stock after buying an additional 16,848 shares during the period. Russell Investments Group Ltd.’s holdings in Xeris Biopharma were worth $61,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in XERS. Wells Fargo & Company MN raised its stake in Xeris Biopharma by 38.7% during the 4th quarter. Wells Fargo & Company MN now owns 79,036 shares of the company’s stock valued at $268,000 after acquiring an additional 22,050 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Xeris Biopharma by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 3,351,426 shares of the company’s stock worth $11,364,000 after purchasing an additional 17,956 shares during the last quarter. AIGH Capital Management LLC lifted its holdings in shares of Xeris Biopharma by 17.8% during the fourth quarter. AIGH Capital Management LLC now owns 2,574,846 shares of the company’s stock worth $8,729,000 after purchasing an additional 389,192 shares during the period. JPMorgan Chase & Co. grew its position in Xeris Biopharma by 166.2% in the 4th quarter. JPMorgan Chase & Co. now owns 1,043,441 shares of the company’s stock valued at $3,537,000 after buying an additional 651,481 shares during the last quarter. Finally, EntryPoint Capital LLC increased its stake in Xeris Biopharma by 52.3% in the 4th quarter. EntryPoint Capital LLC now owns 52,760 shares of the company’s stock valued at $179,000 after buying an additional 18,127 shares during the period. Institutional investors and hedge funds own 42.75% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Piper Sandler restated a “neutral” rating and issued a $4.00 target price (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. Jefferies Financial Group reiterated a “buy” rating and set a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Leerink Partners raised their price target on Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Friday, March 7th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Finally, Craig Hallum increased their price objective on Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a research report on Friday, March 7th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Xeris Biopharma has an average rating of “Moderate Buy” and a consensus target price of $6.10.

Xeris Biopharma Price Performance

XERS opened at $4.31 on Friday. Xeris Biopharma Holdings, Inc. has a 1-year low of $1.71 and a 1-year high of $6.07. The stock has a market cap of $663.48 million, a P/E ratio of -9.58 and a beta of 1.37. The stock’s 50 day simple moving average is $4.50 and its 200 day simple moving average is $3.74.

Insider Activity

In other news, insider Beth Hecht sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total transaction of $217,200.00. Following the completion of the transaction, the insider now directly owns 1,353,510 shares of the company’s stock, valued at $7,349,559.30. This trade represents a 2.87 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 4.56% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.